Clinical Trial

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The study is a multicenter, open-label, phase II clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response (cCR)) of patients with RAS/BRAF wild type locally advanced rectal cancer(LARC) treated with short-term radiotherapy, sequential HLX07, Serplulimab and CAPOX. A total of 29 patients were included in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-04.
Status change: Active, Not Recruiting → Recruiting 2024-12-15
Trial Details
NCT Number NCT06542588
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Rectal Cancer
Enrollment 29 participants
Start Date 2024-07-19
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-18